CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
(2010) In Leukemia & Lymphoma 51. p.1643-1648- Abstract
- We have previously shown that expression of CD40 has a favorable prognostic impact in diffuse large B-cell lymphoma (DLBCL) after anthracycline-based chemotherapy. Here we examined the prognostic value of immunohistochemically defined CD40 expression in 95 patients with DLBCL treated with both anthracycline-based chemotherapy and rituximab. Using a 10% cut-off level, 77% of the patients had CD40-positive tumors and showed a superior overall survival (p = 0.02 log-rank, hazard ratio 0.35, 95% CI 0.14-0.88, p = 0.03 Cox regression). When adjusted for International Prognostic Index in multivariate analysis, CD40 was not an independent prognostic factor (hazard ratio 0.39, 95% CI 0.15-1.04, p = 0.06 Cox regression). However, even after the... (More)
- We have previously shown that expression of CD40 has a favorable prognostic impact in diffuse large B-cell lymphoma (DLBCL) after anthracycline-based chemotherapy. Here we examined the prognostic value of immunohistochemically defined CD40 expression in 95 patients with DLBCL treated with both anthracycline-based chemotherapy and rituximab. Using a 10% cut-off level, 77% of the patients had CD40-positive tumors and showed a superior overall survival (p = 0.02 log-rank, hazard ratio 0.35, 95% CI 0.14-0.88, p = 0.03 Cox regression). When adjusted for International Prognostic Index in multivariate analysis, CD40 was not an independent prognostic factor (hazard ratio 0.39, 95% CI 0.15-1.04, p = 0.06 Cox regression). However, even after the introduction of immunochemotherapy, CD40 has a potential prognostic impact in DLBCL. Additional and larger studies are necessary, regarding the immunohistochemical robustness of CD40 and the biological mechanisms that contribute to the superior prognosis in CD40-expressing DLBCL. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1645362
- author
- Fjordén, Karin LU ; Linderoth, Johan LU ; Nyman, Heidi ; Ehinger, Mats LU ; Joost, Patrick LU ; Bendahl, Pär-Ola LU ; Leppä, Sirpa and Jerkeman, Mats LU
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Leukemia & Lymphoma
- volume
- 51
- pages
- 1643 - 1648
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000282233200010
- pmid:20593977
- scopus:77956324601
- pmid:20593977
- ISSN
- 1029-2403
- DOI
- 10.3109/10428194.2010.492537
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology, (Lund) (013030000), Oncology, MV (013035000)
- id
- 6a36ce2e-5d6e-4298-b459-f5eb0ce888f8 (old id 1645362)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/20593977?dopt=Abstract
- date added to LUP
- 2016-04-04 09:32:42
- date last changed
- 2023-02-24 15:41:41
@article{6a36ce2e-5d6e-4298-b459-f5eb0ce888f8, abstract = {{We have previously shown that expression of CD40 has a favorable prognostic impact in diffuse large B-cell lymphoma (DLBCL) after anthracycline-based chemotherapy. Here we examined the prognostic value of immunohistochemically defined CD40 expression in 95 patients with DLBCL treated with both anthracycline-based chemotherapy and rituximab. Using a 10% cut-off level, 77% of the patients had CD40-positive tumors and showed a superior overall survival (p = 0.02 log-rank, hazard ratio 0.35, 95% CI 0.14-0.88, p = 0.03 Cox regression). When adjusted for International Prognostic Index in multivariate analysis, CD40 was not an independent prognostic factor (hazard ratio 0.39, 95% CI 0.15-1.04, p = 0.06 Cox regression). However, even after the introduction of immunochemotherapy, CD40 has a potential prognostic impact in DLBCL. Additional and larger studies are necessary, regarding the immunohistochemical robustness of CD40 and the biological mechanisms that contribute to the superior prognosis in CD40-expressing DLBCL.}}, author = {{Fjordén, Karin and Linderoth, Johan and Nyman, Heidi and Ehinger, Mats and Joost, Patrick and Bendahl, Pär-Ola and Leppä, Sirpa and Jerkeman, Mats}}, issn = {{1029-2403}}, language = {{eng}}, pages = {{1643--1648}}, publisher = {{Taylor & Francis}}, series = {{Leukemia & Lymphoma}}, title = {{CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.}}, url = {{https://lup.lub.lu.se/search/files/5352750/1685501.pdf}}, doi = {{10.3109/10428194.2010.492537}}, volume = {{51}}, year = {{2010}}, }